Blood sugar's manufacture limited by building blocks' supply

Apr 03, 2007

Researchers have discovered a factor that controls blood sugar's manufacture in a novel way: by limiting the supply of its building blocks. The findings are reported in the April issue of the journal Cell Metabolism, published by Cell Press.

The study found that mice deficient for KLF15, a member of the so-called Krüppel-like family of transcription factors, become severely lacking in the blood sugar glucose—a primary energy source for the body and the sole source for the brain—after a period of overnight fasting. The researchers traced that deficiency back to an inability to produce new glucose in the liver, a process known as gluconeogenesis, due to a defect in the processing of amino acids. Amino acids are the main ingredients of proteins and the source of a key substrate in blood sugar's production.

"Gluconeogenesis is a complicated process," said Mukesh K. Jain of Case Western Reserve University. "It fundamentally requires two big things: the building blocks and the [glucose-building] enzymes that make it all happen. A lot of previous work has focused on the enzymes."

"We've found the first defect [in glucose production] due to a loss of substrate," added Susan Gray of Brigham and Women's Hospital.

During fasting, the supply of glucose derived from food dries up, Gray explained. In response, the body first breaks down liver glycogen, the principal storage form of glucose. However, the body "goes through those stores overnight," she said.

Once the reserves are depleted, the body must rely on the synthesis of new glucose, primarily in the liver, to prevent a life-threatening shortage, a condition known as hypoglycemia. The de novo synthesis of glucose depends on the availability of a substrate molecule that comes from an amino acid.

The researchers found that mice with a targeted deletion of KLF15 display severe hypoglycemia after an overnight fast. They further found evidence that defective amino acid breakdown promotes the development of fasting hypoglycemia in the mutant animals by limiting the availability of a glucose substrate called pyruvate.

Indeed, the mice had markedly reduced activity of genes that encode amino acid-degrading enzymes, the researchers showed. The mice also had a deficiency in the activity of an enzyme that converts the critical amino acid, called alanine, into pyruvate. Consistent with this observation, injection of pyruvate, but not alanine, rescued the mice from their fasting hypoglycemia.

The findings point to a novel form of control over glucose levels, the researchers said. Ultimately, this "window into glucose control" might also have implications for diabetes treatment—a condition characterized by high glucose concentrations, Gray said.

"Inhibiting KLF15 might prove beneficial in people with type II diabetes who have too much glucose, partly because the liver produces more than necessary," Jain said.

"Their glucose sensor is off. If you attenuate KLF15 in the liver, you might limit glucose production."

Gray said she plans to further explore the underlying mechanisms involved in KLF15's glucose regulation and see how increasing KLF15 levels affects blood sugar production. Meanwhile, Jain plans to further examine the transcription factor's function in other parts of the body where it is active, namely in skeletal and heart muscle.

Source: Cell Press

Explore further: Recombinant peptide for transplantation of pancreatic islets in mice models of diabetes

add to favorites email to friend print save as pdf

Related Stories

Italian olive tree disease stumps EU

7 hours ago

EU member states are divided on how to stop the spread of a disease affecting olive trees in Italy that could result in around a million being cut down, officials said Friday.

Festo has BionicANTs communicating by the rules for tasks

7 hours ago

Germany-based automation company Festo, focused on technologies for tasks, turns to nature for inspiration, trying to take the cues from how nature performs tasks so efficiently. "Whether it's energy efficiency, ...

Jury decides Silicon Valley firm did not discriminate

8 hours ago

A jury decided Friday that a prestigious venture capital firm did not discriminate or retaliate against a female employee in a case that shined a light on gender imbalance and working conditions for women ...

Intel in talks with Altera on tie-up

8 hours ago

US tech giant Intel is in talks with rival Altera on a tie-up to broaden the chipmaker's product line amid growth in Internet-connected devices, the Wall Street Journal reported Friday.

Recommended for you

Novel nanoparticle therapy promotes wound healing

Mar 26, 2015

An experimental therapy developed by researchers at Albert Einstein College of Medicine of Yeshiva University cut in half the time it takes to heal wounds compared to no treatment at all. Details of the therapy, ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.